Abstract
Respiratory diseases represent the Czech Republic in the third leading cause of death for women and four for men. They are the most common cause of disability (35.5%, 2011 ÚZIS).
Their prevalence is increasing and has been for decades, these diseases are serious health problems (lung cancer). In the treatment using drugs of various pharmacological groups, are mostly bronchodilators (β2-agonists, anticholinergics), antibiotics, cytostatics, and others.
This article briefly describes the main therapeutic approaches at the top pneumopathies and highlighted the cardiovascular risks that come with this treatment brings.